First-in-Human test for new liver disease drug begins
NCT ID NCT07229911
Summary
This is an early safety study for a new drug called TAK-781. It will first test the drug in healthy volunteers to see if it is safe and how the body processes it. Then, a small group of people with a serious liver disease called primary sclerosing cholangitis (PSC) will receive a single dose to check for early safety signals.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.